These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 18364001)

  • 1. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
    Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
    Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells.
    Donkor MK; Lahue E; Hoke TA; Shafer LR; Coskun U; Solheim JC; Gulen D; Bishay J; Talmadge JE
    Int Immunopharmacol; 2009 Jul; 9(7-8):937-48. PubMed ID: 19362167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis.
    Sinha P; Clements VK; Ostrand-Rosenberg S
    Cancer Res; 2005 Dec; 65(24):11743-51. PubMed ID: 16357187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway.
    Haile LA; von Wasielewski R; Gamrekelashvili J; Krüger C; Bachmann O; Westendorf AM; Buer J; Liblau R; Manns MP; Korangy F; Greten TF
    Gastroenterology; 2008 Sep; 135(3):871-81, 881.e1-5. PubMed ID: 18674538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid derived suppressor cells and their role in tolerance induction in cancer.
    Fujimura T; Mahnke K; Enk AH
    J Dermatol Sci; 2010 Jul; 59(1):1-6. PubMed ID: 20570112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
    Mandruzzato S; Solito S; Falisi E; Francescato S; Chiarion-Sileni V; Mocellin S; Zanon A; Rossi CR; Nitti D; Bronte V; Zanovello P
    J Immunol; 2009 May; 182(10):6562-8. PubMed ID: 19414811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
    Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
    J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
    Solito S; Bronte V; Mandruzzato S
    J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor escape mechanism governed by myeloid-derived suppressor cells.
    Nagaraj S; Gabrilovich DI
    Cancer Res; 2008 Apr; 68(8):2561-3. PubMed ID: 18413722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cell role in tumor-related inflammation.
    Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
    Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.
    Lizée G; Radvanyi LG; Overwijk WW; Hwu P
    Clin Cancer Res; 2006 Aug; 12(16):4794-803. PubMed ID: 16914564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis.
    Ye XZ; Yu SC; Bian XW
    J Genet Genomics; 2010 Jul; 37(7):423-30. PubMed ID: 20659706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based antitumor vaccine.
    Ko HJ; Lee JM; Kim YJ; Kim YS; Lee KA; Kang CY
    J Immunol; 2009 Feb; 182(4):1818-28. PubMed ID: 19201833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid-derived suppressor cells contribute to oral cancer progression in 4NQO-treated mice.
    Chu M; Su YX; Wang L; Zhang TH; Liang YJ; Liang LZ; Liao GQ
    Oral Dis; 2012 Jan; 18(1):67-73. PubMed ID: 21883708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
    Talmadge JE
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5243-8. PubMed ID: 17875751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory cell infiltration of tumors: Jekyll or Hyde.
    Talmadge JE; Donkor M; Scholar E
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):373-400. PubMed ID: 17717638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender dimorphism in the myeloid differentiation of bone marrow precursor cells in a murine host bearing a T cell lymphoma.
    Gupta V; Singh SM
    J Reprod Immunol; 2007 Jun; 74(1-2):90-102. PubMed ID: 17275917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
    Greifenberg V; Ribechini E; Rössner S; Lutz MB
    Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid cell population dynamics in healthy and tumor-bearing mice.
    Ueha S; Shand FH; Matsushima K
    Int Immunopharmacol; 2011 Jul; 11(7):783-8. PubMed ID: 21406269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.